Nowadays, it is well recognized that immune checkpoint inhibitors (ICPIs) targeting the programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis can restore previously suppressed T cell anti-tumor responses and significantly improve survival in many cancers.2 Nevertheless, their role in GBM still remains unclear. The gene discussed is CD274; the disease is cancer.